文献速递糖尿病肥胖与代谢综合征

胰岛素抵抗生物标志物及其预测超重成人治疗反应的表现

Biomarkers of Insulin Resistance and Their Performance as Predictors of Treatment Response in Overweight Adults.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

研究对比高灵敏度ELISA与免疫测定两种胰岛素检测法,利用3个独立队列(META-PREDICT n=179、STRRIDE-AT/RT n=116、STRRIDE-PD n=149)的横断面临床与代谢组学数据构建胰岛素抵抗诊断模型,评估其预测生活方式干预后胰岛素抵抗变化的能力。结果显示两种检测法对国际标准胰岛素定量准确(R2>0.99),但空腹胰岛素一致性较低(R2=0.65);仅ELISA可检测到空腹胰岛素平均治疗效应;临床-代谢组学模型与空腹胰岛素统计相关(R2 0.33-0.39),但分类临床相关HOMA2-IR阈值的胰岛素抵抗能力有限,且无模型能预测任何队列的治疗反应。

要点

  • 两种胰岛素检测法对国际标准胰岛素定量准确(R2>0.99),但空腹胰岛素一致性较低(R2=0.65)。
  • 仅ELISA可检测到空腹胰岛素平均治疗效应,检测法选择对量化治疗影响至关重要。
  • 临床-代谢组学模型与空腹胰岛素相关(R2 0.33-0.39),但分类HOMA2-IR阈值的胰岛素抵抗能力有限。

核心结论

  • 胰岛素检测法的选择对量化治疗对空腹胰岛素的影响至关重要。
  • 横断面研究中识别的临床-代谢组学生物标志物均不适合纵向监测胰岛素抵抗状态的变化。

研究设计与样本

  • 对比高灵敏度ELISA与免疫测定两种胰岛素检测法的表现,并利用横断面临床与代谢组学数据构建胰岛素抵抗诊断模型。
  • 模型用于在干预前空腹样本中对3个独立队列(META-PREDICT n=179、STRRIDE-AT/RT n=116、STRRIDE-PD n=149)的胰岛素抵抗状态进行分层。
  • 采用线性与贝叶斯投影预测策略评估空腹胰岛素、HOMA2-IR及治疗引起的空腹胰岛素变化的模型。

主要发现

  • 两种胰岛素检测法均能准确量化国际标准胰岛素(R2>0.99),但空腹胰岛素间一致性较低(R2=0.65)。
  • 仅ELISA可检测到空腹胰岛素的平均治疗效应。
  • 临床-代谢组学模型与空腹胰岛素统计相关(R2 0.33-0.39),但分类临床相关HOMA2-IR阈值的胰岛素抵抗能力有限。
  • 无模型能预测任何队列的治疗反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Insulin resistance (IR) contributes to the pathogenesis of type 2 diabetes mellitus and is a risk factor for cardiovascular and neurodegenerative diseases. Amino acid and lipid metabolomic biomarkers associate with future type 2 diabetes mellitus risk in several epidemiological cohorts. Whether these biomarkers can accurately monitor changes in IR status following treatment is unclear. OBJECTIVE: Herein we evaluated the performance of clinical and metabolomic biomarker models to forecast altered IR, following lifestyle-based interventions. DESIGN: We contrasted the performance of two distinct insulin assay types (high-sensitivity ELISA and immunoassay) and built IR diagnostic models using cross-sectional clinical and metabolomic data. These models were used to stratify IR status in preintervention fasting samples, from 3 independent cohorts (META-PREDICT (n = 179), STRRIDE-AT/RT (n = 116), and STRRIDE-PD (n = 149)). Linear and Bayesian projective prediction strategies were used to evaluate models for fasting insulin and homeostatic model assessment 2 for insulin resistance and change in fasting insulin with treatment. RESULTS: Both insulin assays accurately quantified international standard insulin (R2 > 0.99), yet agreement between fasting insulins was less congruent (R2 = 0.65). A mean treatment effect on fasting insulin was only detectable using the ELISA. Clinical-metabolomic models were statistically related to fasting insulin (R2 0.33-0.39) but with modest capacity to classify IR at a clinically relevant homeostatic model assessment 2 for insulin resistance threshold. Furthermore, no model predicted treatment responses in any cohort. CONCLUSION: We demonstrate that the choice of insulin assay is critical when quantifying the influence of treatment on fasting insulin, whereas none of the clinical-metabolomic biomarkers, identified in cross-sectional studies, are suitable for monitoring longitudinally changes in IR status.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Brogan RJ, Rooyackers O, Phillips BE, et al. Biomarkers of Insulin Resistance and Their Performance as Predictors of Treatment Response in Overweight Adults. J Clin Endocrinol Metab. 2025. PMID: 40359244. doi:10.1210/clinem/dgaf285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。